Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
Vaccinex, Inc. (VCNX)
Company Research
Source: GlobeNewswire
ROCHESTER, N.Y., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and cancer through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present promising new efficacy and safety data for its randomized, double-blind, phase 1b/2 SIGNAL-AD study of pepinemab treatment for Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, on October 31, 2024. Elizabeth Evans, PhD, Chief Operating Officer and Senior VP Discovery and Translational Medicine, will present results of the study in a podium presentation. Presentation title: Results of SIGNAL-AD, a randomized, phase 1b/2 trial to evaluate safety and efficacy of pepinemab, anti-SEMA4D antibody believed to block reactive astrogliosis, in patients with Mild Cognitive Impairment (MCI) and Mild Dementia due to AD Presenter: Elizabeth Evans, PhD Date: Thur
Show less
Read more
Impact Snapshot
Event Time:
VCNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VCNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VCNX alerts
High impacting Vaccinex, Inc. news events
Weekly update
A roundup of the hottest topics
VCNX
News
- Vaccinex receives delisting notice from Nasdaq, shares down over 49% [Seeking Alpha]Seeking Alpha
- Vaccinex Announces Receipt of Delisting Notification from Nasdaq [Yahoo! Finance]Yahoo! Finance
- Vaccinex Announces Receipt of Delisting Notification from NasdaqGlobeNewswire
- Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
VCNX
Sec Filings
- 12/17/24 - Form 8-K
- 11/18/24 - Form SC
- 11/18/24 - Form 4
- VCNX's page on the SEC website